12.3 Enteral Nutrition: Indications, Formula Selection, Access Routes, and Complications

Enteral Nutrition (EN) involves the delivery of specialized nutritional formulas directly into the gastrointestinal tract via a tube, catheter, or stoma distal to the oral cavity. In clinical dietetics and the NDLE, EN is recognized as the standard of care for patients who possess a functioning gastrointestinal tract but are unable to meet their nutritional requirements through volitional oral intake.

---

The Physiological Supremacy of the Gut: "If the Gut Works, Use It"

The clinical directive "If the gut works, use it" is grounded in clear gastrointestinal physiology and immunology. Total bowel disuse triggers rapid mucosal atrophy within 48 to 72 hours, resulting in devastating systemic consequences:

                     Luminal Nutrients Present
                                 │
        ┌────────────────────────┴────────────────────────┐
        ▼                                                 ▼
[Structural Integrity]                          [Immunological Defense]
- Direct enterocyte fuel (glutamine, butyrate)   - GALT activation (>70% body immunity)
- Sustained villous height & surface area       - Secretory IgA (sIgA) synthesis
- Preserved tight junctions (claudin, occludin)  - Mucosal pathogen neutralization
        │                                                 │
        └────────────────────────┬────────────────────────┘
                                 ▼
                     Barriers Intact & Sealed:
         Prevention of Bacterial Translocation & Endotoxemia
         Attenuated Hypermetabolic Stress & MODS Prevention

1. Maintenance of Mucosal Barrier Integrity

Enterocytes derive up to 70% of their energetic fuel directly from luminal nutrients rather than systemic circulation. The small intestinal mucosa utilizes luminal glutamine, while colonocytes metabolize bacterial-derived short-chain fatty acids (primarily butyrate). In the absence of luminal nutrients:

• Intestinal villi blunt, flatten, and atrophy.
• Epithelial tight junctions (composed of occludins and claudins) loosen and disassemble.
• Intestinal permeability increases drastically, allowing intraluminal bacteria (gram-negative enteric organisms such as Escherichia coli and Klebsiella) and endotoxins (lipopolysaccharides [LPS]) to cross the mucosal basement membrane.
• This phenomenon, termed bacterial translocation, allows pathogens to enter mesenteric lymph nodes, the thoracic duct, and portal blood, fueling systemic bacteremia, systemic inflammatory response syndrome (SIRS), and Multiple Organ Dysfunction Syndrome (MODS).

2. Stimulation of Gut-Associated Lymphoid Tissue (GALT)

Over 70% of the body's total immune system resides within the gastrointestinal tract, configured as Gut-Associated Lymphoid Tissue (GALT), including Peyer's patches, lamina propria lymphocytes, and intraepithelial lymphocytes. Luminal feeding stimulates GALT to produce Secretory Immunoglobulin A (sIgA). Secretory IgA is actively transported across mucosal enterocytes into the gut lumen, where it binds and neutralizes pathogenic bacteria, viruses, and toxins, preventing mucosal adhesion and systemic invasion.

---

Indications and Contraindications for Enteral Feeding

Clinical Indications

Enteral nutrition is indicated when a patient cannot, will not, or should not consume adequate oral nutrients, provided the GI tract is functional:

• Inability to meet $\ge 60\%$ of estimated caloric and protein needs orally for $>5\text{ to }7\text{ days}$ in previously well-nourished patients, or $>3\text{ to }5\text{ days}$ in malnourished patients.
• Severe dysphagia secondary to neurologic disease (cerebrovascular accident, ALS, Guillain-Barré, Parkinson's disease).
• Neoplasms or trauma of the oral cavity, pharynx, larynx, or esophagus.
• Prolonged mechanical ventilation and critical illness.
• Hypermetabolic states (severe burns, polytrauma, major head injury) where oral intake cannot match caloric demands.
• Severe anorexia nervosa or severe failure to thrive.

Contraindications

---

Enteral Access Routes

The selection of an enteral feeding route depends upon two primary factors: the anticipated duration of therapy (threshold: 4 to 6 weeks) and the patient's risk of pulmonary aspiration.

                            Anticipated Duration of EN
                                        │
                ┌───────────────────────┴───────────────────────┐
                ▼                                               ▼
       [Short-Term: <4–6 Weeks]                      [Long-Term: >4–6 Weeks]
                │                                               │
        Aspiration Risk?                                Aspiration Risk?
        ┌───────┴───────┐                               ┌───────┴───────┐
        ▼               ▼                               ▼               ▼
     (Low)            (High)                         (Low)            (High)
  Nasogastric      Nasojejunal /                  Gastrostomy       Jejunostomy
     (NG)         Nasoduodenal (NJ/ND)               (PEG)             (PEJ)

1. Short-Term Access Routes ($<4\text{ to }6\text{ Weeks}$)

• Nasogastric (NG) Tube: Passes through the nose, traversing the esophagus into the stomach. Indicated for patients with intact gastric motility, normal gag reflex, and low aspiration risk. It accommodates all delivery methods (bolus, intermittent, continuous) and takes advantage of normal gastric digestive and antimicrobial reservoir functions.
• Nasoduodenal (ND) and Nasojejunal (NJ) Tubes: Pass through the nose, stomach, and pylorus, terminating in the duodenum or jejunum (distal to the ligament of Treitz). Post-pyloric feeding is indicated for:
  • High pulmonary aspiration risk (severe gastroesophageal reflux, blunted cough/gag reflexes, depressed consciousness).
  • Persistent gastroparesis or delayed gastric emptying.
  • Severe acute pancreatitis (feeding distal to the ligament of Treitz eliminates the cephalic and gastric phases of pancreatic secretion, keeping the exocrine pancreas at rest).
  • Gastric outlet obstruction.

2. Long-Term Access Routes ($>4\text{ to }6\text{ Weeks}$)

• Percutaneous Endoscopic Gastrostomy (PEG): Placed directly into the stomach through the anterior abdominal wall under endoscopic guidance. Standard for long-term enteral feeding. Comfortable, hidden under clothing, preserves normal gastric reservoir physiology, and permits bolus or gravity feedings.
• Percutaneous Endoscopic Jejunostomy (PEJ) / Direct Jejunostomy: Placed directly into the jejunum. Indicated when gastric feeding is contraindicated long-term (gastric carcinoma, prior subtotal/total gastrectomy, severe persistent gastroparesis, recurrent aspiration via PEG). Strictly requires continuous pump infusion.

---

Enteral Formula Classifications and Selection

Commercial enteral formulas are formulated with distinct carbohydrate, protein, lipid, and caloric profiles to match varied gastrointestinal and metabolic capacities:

                           Enteral Formula Spectrum
                                      │
      ┌───────────────────────────────┼───────────────────────────────┐
      ▼                               ▼                               ▼
[Polymeric / Standard]     [Elemental / Monomeric]         [Disease-Specific]
- Intact proteins          - Free amino acids / peptides    - Renal (Nepro: high kcal, low lytes)
- 1.0–1.2 kcal/mL          - MCT-rich lipid fraction        - Pulmonary (high fat, low carb)
- Isosmolal (~300 mOsm)    - Hyperosmolar (>500 mOsm)       - Diabetes (low GI carb, high MUFA)
- Normal digestion         - Malabsorptive disorders        - Hepatic (high BCAA, low AAA)

1. Polymeric (Standard) Formulations

• Macronutrient Composition: Intact protein isolates (caseinates, whey protein, soy protein); complex carbohydrates (maltodextrin, corn syrup solids, hydrolyzed cornstarch); long-chain triglycerides (canola, corn, soy, or sunflower oils).
• Characteristics: Caloric density of $1.0\text{ to }1.2\text{ kcal/mL}$; protein content 30–45 g/L; isosmolal ($\approx 300\text{ to }400\text{ mOsm/kg}$); provides approximately 80% to 85% free water.
• Clinical Indications: Patients with intact digestive and absorptive capacities who require supplemental or total nutrition support.

2. Concentrated / Calorie-Dense Formulations

• Characteristics: Caloric density of $1.5\text{ to }2.0\text{ kcal/mL}$; high protein content (60–90 g/L); reduced free water content ($68\%\text{ to }76\%$).
• Clinical Indications: Severe fluid-restricted states: Congestive Heart Failure (CHF), oliguric Acute Kidney Injury (AKI) or Chronic Kidney Disease (CKD), Syndrome of Inappropriate Antidiuretic Hormone (SIADH), severe peripheral/pulmonary edema.

3. Elemental (Monomeric) and Semi-Elemental (Oligomeric) Formulations

• Macronutrient Composition: Hydrolyzed peptides (di- and tri-peptides, which are absorbed more rapidly and efficiently via the enterocyte PepT1 transporter than free amino acids) or pure crystalline free L-amino acids. Carbohydrates are provided as short-chain maltodextrins or glucose oligosaccharides.
• Lipid Fraction & Medium-Chain Triglycerides (MCTs): Contains minimal long-chain triglycerides (LCTs) and a high fraction of MCTs ($C_8\text{ to }C_{10}$, caprylic and capric acids). MCTs possess unique biochemical properties:
  • They are water-soluble and can be absorbed directly across enterocyte membranes without requiring emulsification by bile salts or cleavage by pancreatic lipase.
  • They do not form chylomicrons and do not traverse the thoracic duct; instead, they absorb directly into the portal vein bound to albumin, traveling directly to the liver.
• Characteristics: Hyperosmolar ($450\text{ to }700+\text{ mOsm/kg}$); requires slow initial infusion rates to prevent osmotic diarrhea.
• Clinical Indications: Severe malabsorption syndromes, Short Bowel Syndrome, chronic pancreatitis with pancreatic exocrine insufficiency, severe Crohn's disease exacerbation, radiation enteritis, chylothorax, and chylous ascites.

4. Disease-Specific Specialized Formulations

---

Enteral Administration Modalities

1. Continuous Infusion:
   • Method: Administered continuously over 24 hours at a steady, controlled rate using an electronic volumetric infusion pump.
   • Indications: Critically ill patients, post-pyloric (duodenal or jejunal) feedings, patients experiencing gastrointestinal intolerance, or patients with unstable blood glucose.
2. Cyclic Infusion:
   • Method: Administered via infusion pump over a compressed time frame ($8\text{ to }16\text{ hours}$, typically overnight).
   • Indications: Promotes daytime mobility and rehabilitation; allows daytime appetite to return during the transition from tube feeding to oral diet.
3. Intermittent Gravity Drip:
   • Method: Infusion of $200\text{ to }400\text{ mL}$ of formula over $30\text{ to }60\text{ minutes}$, repeated 4 to 6 times daily via a gravity flow bag.
   • Indications: Gastric feeding only; provides a regular meal-like pattern for stable rehabilitation patients.
4. Bolus Feeding:
   • Method: Rapid delivery of $200\text{ to }400\text{ mL}$ of formula over $10\text{ to }20\text{ minutes}$ using a 60-mL catheter-tip syringe by gravity or gentle plunger action, administered 4 to 6 times daily.
   • Indications: Strictly limited to gastric feeding (NG or PEG) in alert, stable patients with normal gastric emptying and intact gag reflex. Simulates physiological meal schedules and requires no expensive pump equipment.

---

Complications of Enteral Nutrition and Evidence-Based Management

1. Gastrointestinal Complications: Enteral Diarrhea Workup

Diarrhea (defined as $>3\text{ to }5$ liquid stools/day or $>200–300\text{ g/day}$) occurs in 15% to 30% of enterally fed patients. The clinical dietitian must execute an ordered, systematic diagnostic workup:

                             Enteral Diarrhea Arises
                                        │
                                        ▼
                     [Step 1: Stool Microbiology Assay]
                      Test for Clostridioides difficile toxin
                      DO NOT give antimotility agents (loperamide)
                                        │
               ┌────────────────────────┴────────────────────────┐
               ▼ (Positive)                                      ▼ (Negative)
        Initiate Vancomycin /                     [Step 2: Liquid Medication Audit]
        Fidaxomicin Medical Rx                     Inspect elixirs for SORBITOL content
                                                   (e.g., acetaminophen, theophylline)
                                                   Audit antibiotics & magnesium antacids
                                                                 │
                                                                 ▼
                                                  [Step 3: EN Formula & Administration]
                                                   - Check hang time (open: 8–12h, closed: 24–48h)
                                                   - Slow the infusion rate
                                                   - Add soluble fiber (guar gum, banana flakes)
                                                   - Trial semi-elemental / peptide formula

• Rule Out Clostridioides difficile: Never administer antidiarrheal antimotility agents (loperamide, diphenoxylate/atropine) before ruling out C. diff via stool PCR or toxin assay. Halting gut motility during active toxigenic C. diff colitis risks precipitating toxic megacolon and bowel perforation.
• Medication Audit for Sorbitol: Liquid oral elixirs and syrups (acetaminophen, theophylline, furosemide, potassium chloride) frequently contain large amounts of sorbitol as an artificial sweetener/excipient. Ingestion of as little as $10\text{ to }20\text{ g/day}$ of sorbitol exerts a massive osmotic draw into the colonic lumen, producing severe iatrogenic osmotic diarrhea. Switch liquid medications to crushed tablets (if approved) or IV formulations.
• Hang Time Hygiene: Contaminated enteral formula can cause infectious diarrhea. Open system containers (where formula is poured into a bag from cans) have a strict maximum hang time of $8\text{ to }12\text{ hours}$. Closed, pre-filled, sterile ready-to-hang containers have a safe hang time of $24\text{ to }48\text{ hours}$.
• Fiber Modification: Adding soluble, fermentable fiber (partially hydrolyzed guar gum, pectin, banana flakes) provides substrates for colonic microflora to generate short-chain fatty acids (SCFAs). SCFAs stimulate colonic sodium and water reabsorption, firming liquid stools.

2. Gastric Residual Volume (GRV) Management and Aspiration Prevention

• Aspiration Prevention: Pulmonary aspiration of gastric contents is the most hazardous complication of enteral nutrition. Maintain the Head of Bed (HOB) elevated at $30^\circ\text{ to }45^\circ$ at all times during feeding and for at least 30 to 60 minutes after intermittent feeds.
• Modern GRV Consensus: Historic practices of holding feeds for GRVs of 150 to 200 mL are obsolete and lead to severe under-delivery of nutrition. Current ASPEN/SCCM guidelines state:
  • Routine monitoring of GRV is not recommended in ICU patients without overt signs of intolerance.
  • Where monitored, do not hold enteral feeding for GRVs $<500\text{ mL}$ in the absence of other symptoms of GI intolerance (nausea, emesis, abdominal distension, absent bowel sounds).
  • If gastric intolerance occurs, consider advancing the tube post-pyloric or initiating a prokinetic agent (metoclopramide 10 mg IV or erythromycin 100–250 mg IV).

3. Mechanical Complications: Tube Clogging

• Etiology: Tube occlusion results from formula curdling, inadequate water flushing, or improper medication administration (mixing crushed tablets directly into the formula, or administering whole pills).
• Prevention Protocol: Flush feeding tubes with $30\text{ mL}$ of warm tap or sterile water:
  • Every 4 hours during continuous feeding.
  • Before and after each intermittent or bolus feeding.
  • Before and after each individual medication administration (flush with 5–10 mL between medications).
  • Before and after checking gastric residual volumes.
• Restoring Patency:
  • Instill warm water with a 30-mL or 60-mL syringe using a gentle push-pull plunger technique.
  • If water fails, instill an activated pancreatic enzyme mixture: crush one pancreatic enzyme tablet (e.g., Creon, Viokace) and dissolve with one 325-mg sodium bicarbonate tablet in 5–10 mL of warm water. Instill into the tube, clamp for 30 to 60 minutes, and flush with warm water.
  • PROHIBITED: Never instill acidic carbonated beverages (cola), cranberry juice, or meat tenderizers. The acid causes intact caseinate proteins in enteral formulas to precipitate immediately, creating an intractable, rock-hard intraluminal obstruction!